Outcomes and Costs Associated With Initial Maintenance Therapy With Fluticasone Propionate-Salmeterol Xinafoate 250 μg/50 μg Combination Versus Tiotropium In Commercially Insured Patients With COPD

Anand A. DalalPhD

首页> 外文期刊>Managed care >Outcomes and Costs Associated With Initial Maintenance Therapy With Fluticasone Propionate-Salmeterol Xinafoate 250 μg/50 μg Combination Versus Tiotropium In Commercially Insured Patients With COPD

【24h】

Outcomes and Costs Associated With Initial Maintenance Therapy With Fluticasone Propionate-Salmeterol Xinafoate 250 μg/50 μg Combination Versus Tiotropium In Commercially Insured Patients With COPD

机译：在商业保险的COPD患者中使用丙酸氟替卡松-沙美特罗新萘酯250μg/ 50μg联合噻托溴铵进行初始维持治疗的相关结果和费用

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Managed care》 |2011年第8期|共页
作者
Anand A. DalalPhD;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类文教、卫生管理法令;
关键词

相似文献

外文文献
中文文献

1. Outcomes and Costs Associated With Initial Maintenance Therapy With Fluticasone Propionate-Salmeterol Xinafoate 250 μg/50 μg Combination Versus Tiotropium In Commercially Insured Patients With COPD [J] . Managed care . 2011,第2011期

机译：在商业保险的COPD患者中使用丙酸氟替卡松-沙美特罗新萘酯250μg/ 50μg联合噻托溴铵进行初始维持治疗的相关结果和费用
2. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population [J] . Anand A Dalal, Manan Shah, Anna O DSouza, International Journal of Chronic Obstructive Pulmonary Disease . 2012,第1期

机译：在合并的COPD /抑郁症人群中开始丙酸氟替卡松/沙美特罗联合治疗（250/50 mcg）与抗胆碱能药的患者的临床和经济结果
3. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial – Evaluation of Airway sGaw after treatment with tripLE [Corrigendum] [J] . International Journal of Chronic Obstructive Pulmonary Disease . 2016,第1期

机译：与中度至重度日本慢性阻塞性肺病患者的个别治疗相比，沙美特罗/丙酸氟替卡松50/250联合噻托溴铵三联疗法改善肺功能：一项随机对照试验–三联疗法治疗后对气道sGaw的评估[勘误]
4. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
5. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial – Evaluation of Airway sGaw after treatment with tripLE Corrigendum [O] . 2016

机译：与中度至重度日本COPD患者的单独治疗相比沙美特罗/丙酸氟替卡松50/250加溴化噻托溴铵的三联疗法改善肺功能：一项随机对照试验–三联疗法治疗后对气道sGaw的评估勘误
6. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population [O] . Dalal, Anand A, Shah, Manan, D’Souza, Anna O, 2012

机译：在COPD /抑郁症合并症患者中丙酸氟替卡松/沙美特罗联合治疗（250/50 mcg）与抗胆碱能药的患者的临床和经济结局

Outcomes and Costs Associated With Initial Maintenance Therapy With Fluticasone Propionate-Salmeterol Xinafoate 250 μg/50 μg Combination Versus Tiotropium In Commercially Insured Patients With COPD

著录项

相似文献

相关主题

期刊订阅